Icecure Medical Ltd Ord (ICCM)

$0.67 +0.01 (1.02%)
Market Cap 45.80M
Revenue (ttm) 3.29M
Net Income (ttm) -15.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -465.65%
Debt to Equity Ratio 0.00
Volume 253,300
Avg Vol 428,374
Day's Range N/A - N/A
Shares Out 68.70M
Stochastic %K 51%
Beta 0.28
Analysts Strong Sell
Price Target $3.05

Company Profile

IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic...

Industry: Medical Devices
Sector: Healthcare
Phone: 972 4 623 0333
Fax: 972 4 623 0222
Address:
7 Ha’Eshel Street, PO Box 3163, Caesarea, Israel
grandpa_dirt
grandpa_dirt Dec. 25 at 7:55 PM
$ICCM Got an e-mail for a proxy vote. I guess the meeting next month is mostly to increase salaries.
0 · Reply
ComprehensionCore
ComprehensionCore Dec. 25 at 5:32 PM
$ICCM The investment case increasingly rests on operational credibility rather than long‑range promises. Structural initiatives require practical follow‑through to gain credibility. Evidence of resilience during turbulence would be constructive. Catalysts matter, yet consistency will ultimately carry more weight.
1 · Reply
Ericmao
Ericmao Dec. 24 at 5:13 PM
$ICCM buy buy buy !!! Big day coming !!!
0 · Reply
Shanenobody
Shanenobody Dec. 24 at 1:13 PM
$ICCM https://finance.yahoo.com/video/biopharma-2026-outlook-keep-eye-113006270.html
0 · Reply
Shanenobody
Shanenobody Dec. 23 at 6:05 PM
$ICCM ICCM is going to release preliminary sales figures in January. Hopefully this will raise share price. This could also make them more attractive for a buyout. If the price goes high enough after releasing preliminary sales numbers, the buyout price will also increase. Fingers crossed.
0 · Reply
SuperBusa
SuperBusa Dec. 22 at 3:17 PM
$ICCM
0 · Reply
Biorocksme
Biorocksme Dec. 22 at 7:51 AM
$ICCM Under a dollar. Needs cash. Reverse split possible later if market keeps this in the penny dumpster. Price is the boss.
1 · Reply
thechad369
thechad369 Dec. 19 at 5:11 AM
$ICCM pretty clear the only way for this to hold a gain is going to be a buyout. Not even fundamental news is holding
1 · Reply
SuperBusa
SuperBusa Dec. 18 at 7:42 PM
$ICCM
0 · Reply
Joe_088
Joe_088 Dec. 18 at 12:36 PM
$ICCM ProSense® systems are being sold and installed at new locations across North America, including some of the most highly regarded medical institutions in the United States
1 · Reply
Latest News on ICCM
IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer

Dec 17, 2025, 8:30 AM EST - 9 days ago

IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer

IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting

Dec 10, 2025, 8:30 AM EST - 16 days ago

IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

Dec 5, 2025, 8:30 AM EST - 21 days ago

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

IceCure Medical Ltd (ICCM) Q3 2025 Earnings Call Transcript

Nov 19, 2025, 12:53 PM EST - 5 weeks ago

IceCure Medical Ltd (ICCM) Q3 2025 Earnings Call Transcript

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

Nov 19, 2025, 8:54 AM EST - 5 weeks ago

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

Nov 18, 2025, 8:30 AM EST - 5 weeks ago

IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

Nov 14, 2025, 4:30 PM EST - 5 weeks ago

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

Nov 12, 2025, 8:30 AM EST - 6 weeks ago

IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

Nov 10, 2025, 8:30 AM EST - 6 weeks ago

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

Nov 3, 2025, 8:30 AM EST - 7 weeks ago

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

Oct 13, 2025, 8:30 AM EDT - 2 months ago

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

IceCure Medical to Attend the 2025 Maxim Growth Summit

Oct 9, 2025, 8:30 AM EDT - 2 months ago

IceCure Medical to Attend the 2025 Maxim Growth Summit

IceCure Medical Ltd - Special Call

Oct 6, 2025, 11:25 AM EDT - 2 months ago

IceCure Medical Ltd - Special Call

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

Oct 3, 2025, 12:28 PM EDT - 2 months ago

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

Oct 3, 2025, 12:19 PM EDT - 2 months ago

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

Sep 30, 2025, 8:30 AM EDT - 3 months ago

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented

Sep 22, 2025, 8:30 AM EDT - 3 months ago

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes

Sep 18, 2025, 8:30 AM EDT - 3 months ago

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes

IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications

Sep 15, 2025, 8:30 AM EDT - 3 months ago

IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

Sep 8, 2025, 8:30 AM EDT - 3 months ago

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy

Sep 4, 2025, 8:30 AM EDT - 4 months ago

IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy

IceCure Medical Ltd (ICCM) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 1:08 PM EDT - 4 months ago

IceCure Medical Ltd (ICCM) Q2 2025 Earnings Call Transcript

IceCure Reports Financial & Operational Results for the First Half of 2025

Aug 13, 2025, 8:30 AM EDT - 4 months ago

IceCure Reports Financial & Operational Results for the First Half of 2025

IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025

Aug 6, 2025, 8:30 AM EDT - 5 months ago

IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025

IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million

Jul 29, 2025, 9:00 AM EDT - 5 months ago

IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

Jul 25, 2025, 9:00 AM EDT - 5 months ago

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period

Jul 24, 2025, 9:00 AM EDT - 5 months ago

IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period

IceCure Announces Commencement of Rights Offering

Jul 10, 2025, 8:00 AM EDT - 6 months ago

IceCure Announces Commencement of Rights Offering

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

Jul 3, 2025, 8:30 AM EDT - 6 months ago

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

IceCure Announces Record Date for Rights Offering for Up to $10 Million

Jun 25, 2025, 9:23 AM EDT - 6 months ago

IceCure Announces Record Date for Rights Offering for Up to $10 Million

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

Jun 9, 2025, 8:30 AM EDT - 7 months ago

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

IceCure Medical Ltd (ICCM) Q1 2025 Earnings Call Transcript

May 28, 2025, 4:26 PM EDT - 7 months ago

IceCure Medical Ltd (ICCM) Q1 2025 Earnings Call Transcript

IceCure Medical Reports First Quarter 2025 Financial Results

May 28, 2025, 8:30 AM EDT - 7 months ago

IceCure Medical Reports First Quarter 2025 Financial Results

IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

May 21, 2025, 8:30 AM EDT - 7 months ago

IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

May 6, 2025, 8:30 AM EDT - 8 months ago

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

Apr 30, 2025, 8:30 AM EDT - 8 months ago

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

Apr 28, 2025, 8:30 AM EDT - 8 months ago

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

Apr 22, 2025, 8:30 AM EDT - 8 months ago

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 1:45 PM EDT - 9 months ago

IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

Mar 27, 2025, 8:30 AM EDT - 9 months ago

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

Mar 24, 2025, 8:30 AM EDT - 9 months ago

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

Mar 21, 2025, 8:30 AM EDT - 10 months ago

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

Mar 20, 2025, 8:30 AM EDT - 10 months ago

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference

Mar 18, 2025, 8:30 AM EDT - 10 months ago

IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference

IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology

Mar 17, 2025, 8:30 AM EDT - 10 months ago

IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology

Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery

Mar 10, 2025, 8:30 AM EDT - 10 months ago

Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery

IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel

Feb 24, 2025, 8:30 AM EST - 10 months ago

IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel

IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision

Feb 4, 2025, 8:30 AM EST - 11 months ago

IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision

IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

Jan 27, 2025, 8:30 AM EST - 11 months ago

IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America

Jan 13, 2025, 7:00 AM EST - 1 year ago

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America

grandpa_dirt
grandpa_dirt Dec. 25 at 7:55 PM
$ICCM Got an e-mail for a proxy vote. I guess the meeting next month is mostly to increase salaries.
0 · Reply
ComprehensionCore
ComprehensionCore Dec. 25 at 5:32 PM
$ICCM The investment case increasingly rests on operational credibility rather than long‑range promises. Structural initiatives require practical follow‑through to gain credibility. Evidence of resilience during turbulence would be constructive. Catalysts matter, yet consistency will ultimately carry more weight.
1 · Reply
Ericmao
Ericmao Dec. 24 at 5:13 PM
$ICCM buy buy buy !!! Big day coming !!!
0 · Reply
Shanenobody
Shanenobody Dec. 24 at 1:13 PM
$ICCM https://finance.yahoo.com/video/biopharma-2026-outlook-keep-eye-113006270.html
0 · Reply
Shanenobody
Shanenobody Dec. 23 at 6:05 PM
$ICCM ICCM is going to release preliminary sales figures in January. Hopefully this will raise share price. This could also make them more attractive for a buyout. If the price goes high enough after releasing preliminary sales numbers, the buyout price will also increase. Fingers crossed.
0 · Reply
SuperBusa
SuperBusa Dec. 22 at 3:17 PM
$ICCM
0 · Reply
Biorocksme
Biorocksme Dec. 22 at 7:51 AM
$ICCM Under a dollar. Needs cash. Reverse split possible later if market keeps this in the penny dumpster. Price is the boss.
1 · Reply
thechad369
thechad369 Dec. 19 at 5:11 AM
$ICCM pretty clear the only way for this to hold a gain is going to be a buyout. Not even fundamental news is holding
1 · Reply
SuperBusa
SuperBusa Dec. 18 at 7:42 PM
$ICCM
0 · Reply
Joe_088
Joe_088 Dec. 18 at 12:36 PM
$ICCM ProSense® systems are being sold and installed at new locations across North America, including some of the most highly regarded medical institutions in the United States
1 · Reply
Joe_088
Joe_088 Dec. 18 at 8:37 AM
$ICCM
0 · Reply
bigcucus35
bigcucus35 Dec. 17 at 6:04 PM
$ICCM how many shares does everyone own?
2 · Reply
Joe_088
Joe_088 Dec. 17 at 6:02 PM
$ICCM In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Icecure Medical, with a price target of $3.00.
0 · Reply
Tetroman
Tetroman Dec. 17 at 6:01 PM
$ICCM anyone have a clue why would they share numbers before time?
4 · Reply
Joe_088
Joe_088 Dec. 17 at 6:00 PM
$ICCM
0 · Reply
bert89
bert89 Dec. 17 at 5:57 PM
$PCSA $ICCM Get in before its too late
0 · Reply
bert89
bert89 Dec. 17 at 5:56 PM
$TSLA Check out $ICCM
0 · Reply
DARKP00L
DARKP00L Dec. 17 at 5:37 PM
$ICCM 12:23 on Dec. 17 2025 IceCure Medical shares are trading higher after the company announced that it expects a significant increase in Q4 sales in North America following the recent FDA clearance of ProSense Cryoablation for low-risk breast cancer. #tradeideas
0 · Reply
Joe_088
Joe_088 Dec. 17 at 3:38 PM
$PCSA 👉 $ICCM
0 · Reply
MahiMe
MahiMe Dec. 17 at 3:14 PM
$ICCM IceCure plans to report preliminary top-line revenue results in January 2026 followed by its full annual report on Form 20-F in April 2026. https://finance.yahoo.com/news/icecure-expected-report-record-fourth-133000676.html
0 · Reply
SuperBusa
SuperBusa Dec. 17 at 3:01 PM
$ICCM
0 · Reply
Joe_088
Joe_088 Dec. 17 at 2:48 PM
$ICCM ProSense® systems are being sold and installed at new locations across North America, including some of the most highly regarded medical institutions in the United States📈📈
0 · Reply